Amneal Pharmaceuticals, Inc. (AMRX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Amneal Pharmaceuticals, Inc. (AMRX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 49/100 — a percentile rank of Amneal Pharmaceuticals, Inc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $7.0B |
| P / E | 44.4× |
| P / S | 2.2× |
| EV / EBITDA | 14.3× |
| Gross margin | 39.3% |
| Operating margin | 14.4% |
| Net margin | 6.9% |
| Return on equity | 476.5% |
| ROIC | 18.1% |
| Revenue growth | 9.3% |
| Debt / equity | 80.9× |
| Dividend yield | 0.0% |
Is Amneal Pharmaceuticals, Inc. overvalued? P/E looks fair vs its 5-year range; P/S looks overvalued vs its 5-year range; EV/EBITDA looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Amneal Pharmaceuticals, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact